From the Department of Medicine (Dr Hung) and The Carol Yu Centre for Infection and Division of Infectious Diseases (Drs Hung and Yuen), State Key Laboratory of Emerging Infectious Diseases, Queen Mary Hospital, The University of Hong Kong.
Correspondence to: Ivan F. N. Hung, MD, Administrative Block 808, Queen Mary Hospital, 102 Pokfulam Rd, Hong Kong SAR, China; e-mail: firstname.lastname@example.org
Financial/nonfinancial disclosures: The authors have reported to CHEST that no potential conflicts of interest exist with any companies/organizations whose products or services may be discussed in this article.
Reproduction of this article is prohibited without written permission from the American College of Chest Physicians. See online for more details.
We thank Dr Raschke for his comments on our article on hyperimmune IV immunoglobulin treatment.1 The subgroup analysis of the 22 patients who received treatment within 5 days of symptom onset was based on the fact that the viral load between the treatment and control arms became significantly different on day 5 from symptom onset (3.3 log10 copies/mL vs 4.67 log10 copies/mL, P = .04). We agree with Dr Raschke that there is a limitation in performing such a subgroup analysis, and we should have stated the plan to perform subgroup analysis according to the viral load result in the Materials and Methods section.
Become a CHEST member and receive a FREE subscription as a benefit of membership.
Individuals can purchase this article on ScienceDirect.
Individuals can purchase a subscription to the journal.
Individuals can purchase a subscription to the journal or buy individual articles.
Learn more about membership or Purchase a Full Subscription.
Institutional access is now available through ScienceDirect and can be purchased at myelsevier.com.
Some tools below are only available to our subscribers or users with an online account.
Download citation file:
Web of Science® Times Cited:
Customize your page view by dragging & repositioning the boxes below.
Enter your username and email address. We'll send you a reminder to the email address on record.
Athens and Shibboleth are access management services that provide single sign-on to protected resources. They replace the multiple user names and passwords necessary to access subscription-based content with a single user name and password that can be entered once per session. It operates independently of a user's location or IP address. If your institution uses Athens or Shibboleth authentication, please contact your site administrator to receive your user name and password.